{"_id": "650139dafddc0bb1312fb032", "and": [{"$and": [{"cancer type": "melanoma"}, {"metastasis to brain": true}]}, {"$and": [{"primary tumor origin": {"$in": ["cutaneous", "acral/mucosal", "unknown"]}}, {"primary tumor origin": {"$ne": "uveal"}}]}, {"BRAF-V600 mutation": true}, {"$and": [{"days since brain MRI": {"$lt": 28}}, {"brain metastasis size": {"$gte": 0.5}}, {"brain metastasis size": {"$ne": "irradiated"}}, {"brain metastasis size": {"$ne": "progressed"}}, {"MRI slice thickness": {"$lte": 1.5}}, {"CT of head": false}, {"CNS disease documented": true}]}, {"extracranial disease": true}, {"disease assessment documented": true}, {"leptomeningeal disease": true}, {"corticosteroids dose": {"$lte": 8}}, {"Zubrod performance status": {"$lte": 2}}, {"days since history and physical examination": {"$lt": 28}}, {"able to swallow and retain pills": true}, {"Hemoglobin": {"$gte": 8}}, {"Absolute neutrophil count": {"$gte": 1500}}, {"Platelets": {"$gte": 75000}}, {"Total bilirubin": {"$lte": 1.5}}, {"AST and ALT": {"$lte": 2.5}}, {"Creatinine": {"$lte": 2}}, {"cardiac risk assessment": {"$in": ["2B", "better"]}}, {"prior or concurrent malignancy": true}, {"HIV infection status": {"$ne": "positive"}}, {"HCV infection status": {"$ne": "positive"}}, {"image banking": true}, {"specimen and blood collections": true}, {"informed consent": true}, {"institutional review board approval": {"$gte": 365}}], "$not": {"$or": [{"prior systemic therapy for metastatic disease": true}, {"days since prior radiation therapy": {"$lt": 7}}, {"additional systemic anti-tumor therapy": true}, {"use of hormonal contraceptives": true}, {"serious active infection": true}, {"active autoimmune disease": true}, {"immune-related adverse events": true}, {"adverse events related to encorafenib and/or binimetinib": true}, {"pregnant or nursing": true}]}, "nctId": "NCT04511013", "title": "A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases"}